We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation (ENSURE)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01232335
First Posted: November 2, 2010
Last Update Posted: May 29, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
October 31, 2010
November 2, 2010
May 29, 2013
January 2010
May 2013   (Final data collection date for primary outcome measure)
Incidence of Adverse Events [ Time Frame: Range of one year ]
Same as current
Complete list of historical versions of study NCT01232335 on ClinicalTrials.gov Archive Site
  • The level of asthma control under long-term use [ Time Frame: At the end of 24 weeks ]
  • The level of asthma control under long-term use [ Time Frame: At the end of one year ]
Same as current
Not Provided
Not Provided
 
Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation
Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation for Long-term Use
The purpose of this study is to confirm the safety profile for long term treatment and maximize doses and the control status on bronchial asthma in daily clinical usage
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients treated with Symbicort for the first time due to bronchial asthma
Bronchial Asthma
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1500
May 2013
May 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients treated with Symbicort for the first time possibly at the higher dose due to bronchial asthma

Exclusion Criteria:

Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT01232335
D589IC00001
No
Not Provided
Not Provided
AstraZeneca
AstraZeneca
Not Provided
Study Director: Yoshida Shigeru AstraZeneca K.K.
AstraZeneca
May 2013